Product
AI AGENTS
INTELLIGENCE SUITE
API, MCP & INTEGRATION
Solutions
INDUSTRIES
USE CASES
Pricing
Resources
EXPLORE
ENGAGE
SUPPORT & SERVICES
About
Patsnap Eureka Platform
IP Search Agents
IP Drafting Agents
Engineering Agents
Find Solutions with TRIZ
Life Sciences Agents
Materials Agents
SEP Agents
Patsnap Eureka Desktop
BetaAnalytics
IP IntelligenceSynapse
Biopharma IntelligenceBio
Biosequence Search and AnalysisChemical
Chemical Structure Search and AnalysisProfessional Services
Open Platform
Developer Center
Customer Stories
Newsroom
Blog
Global Innovation Report
Glossary
Free tools
NEWWebinars & Training
User Community
R&D Benchmark Calculator
Trust and Security
PatentBench
NEWLLM
Help center
Careers
Access to over 2,000,000,000 structured data points around patents, science, litigation, and tech sectors
Innovate 75% faster at 25% less cost
Cloud or on-prem for maximum privacy and control
Trusted by more than 18,000 innovators worldwide
To use , click the vertification button in the email we sent to [email protected].
This helps keep your account secure.
You should receive it shortly. Don’t forget to check your spam folder.
Already have an account? Log In
To start using Patsnap Eureka, click the verification button in the email we sent to .
This helps keep your account secure.
Haven't received it? Check your spam folder.
Thoughtfully curated series offering valuable insights for innovation professionals
Article | Report How does cipaglucosidase alfa/miglustat compare to avalglucosidase alfa in Pompe disease? Explore the IP, clinical trial data, and competitive dynamics shaping the next-generation ERT race.
Article | Report How engineers validate long-term corrosion resistance of titanium dental implant surfaces using electrochemical and simulated physiological test methods.
Article | Report The anti-counterfeiting materials landscape in 2026: key technology approaches, innovation trends, and how to navigate patent intelligence in brand protection.
Article | Report How lixisenatide-class GLP-1 receptor agonists protect the brain: ELAD MS trial design, LixiPark Phase II data, and the patent landscape driving neurodegeneration R&D.
Article | Report How machine-learned potentials, graph neural networks, and self-driving labs are compressing catalyst discovery timescales in energy transition and industrial chemistry.
Article | Report Explore the luminescent solar concentrator materials landscape in 2026: quantum dots, perovskites, organic dyes, and the patent intelligence shaping LSC innovation.
Article | Report How AI-powered process optimization is transforming energy consumption management in continuous chemical manufacturing — key approaches, research directions, and innovation intelligence.
Article | Report Mapping the 2026 lipidomics profiling landscape: LC-HRMS, ion mobility, computational tools, clinical standardization, and emerging directions across 15+ countries.
Article | Report COMP360 psilocybin enters Phase III for treatment-resistant depression as MindMed's MM-120 advances in GAD. Analyse the readout race, trial design, and IP landscape.
Article | Report What are the main technical challenges of integrating neuromorphic computing chips into real-time robotic perception systems? A deep-dive for R&D and IP teams.
Article | Report Explore the graphene oxide functionalization landscape in 2026: patent strategies, application domains, and how R&D teams can build a rigorous GO intelligence pipeline.
Article | Report Explore the key engineering differences between static and dynamic seal design in high-pressure cryogenic fluid systems — covering materials, leakage, and thermal cycling.
Article | Report Explore the 2026 technology landscape for biomass-derived carbon materials — biochar, activated carbon, hydrochar — and how PatSnap Eureka maps innovation.
Article | Report Mapping the 2026 continuous ketone monitor patent landscape: dual-analyte biosensors, breath acetone sensing, and wearable metabolic platforms reshaping diabetes care.
Article | Report Etavopivat (FT-4202) activates pyruvate kinase R to induce fetal hemoglobin without genome editing. Explore Phase 2/3 PEARL trial data and Novo Nordisk's IP strategy.